Swiss National Bank Sells 17,300 Shares of Revvity, Inc. (NYSE:RVTY)

Swiss National Bank lessened its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 348,400 shares of the company's stock after selling 17,300 shares during the period. Swiss National Bank owned 0.29% of Revvity worth $38,885,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Gladius Capital Management LP acquired a new position in Revvity in the third quarter valued at about $32,000. Assetmark Inc. lifted its stake in Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after buying an additional 259 shares during the period. Continuum Advisory LLC lifted its stake in Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock valued at $43,000 after buying an additional 327 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Revvity by 55.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after buying an additional 138 shares during the period. Finally, Avior Wealth Management LLC lifted its stake in Revvity by 7,980.0% in the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after buying an additional 399 shares during the period. Institutional investors own 86.65% of the company's stock.

Insider Transactions at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.

Remove Ads

Revvity Price Performance

NYSE RVTY traded down $2.96 during midday trading on Thursday, hitting $106.96. The company had a trading volume of 1,078,605 shares, compared to its average volume of 847,269. The company has a market capitalization of $12.85 billion, a PE ratio of 48.40, a P/E/G ratio of 3.82 and a beta of 1.06. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $116.76 and a 200-day moving average price of $117.74. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the firm posted $1.25 earnings per share. As a group, analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. Revvity's dividend payout ratio (DPR) is currently 12.67%.

Wall Street Analyst Weigh In

RVTY has been the topic of a number of research analyst reports. Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target on the stock in a research report on Friday, December 13th. Raymond James restated an "outperform" rating and issued a $145.00 price target (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Barclays raised their price target on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. KeyCorp raised their price target on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein downgraded Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Revvity currently has an average rating of "Moderate Buy" and an average price target of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.